Peer-reviewed veterinary case report
Autoimmune lymphoproliferative syndrome in Boerboel dogs treatment
By Tong, Linda J et al.·Published in Journal of veterinary internal medicine·2026·Internal Medicine, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Autoimmune lymphoproliferative syndrome in Boerboel dogs: treatment, clinical outcomes and prevention.
- Species:
- dog
Plain-English summary
A group of Boerboel puppies was diagnosed with a rare genetic disorder called autoimmune lymphoproliferative syndrome (ALPS), which caused swollen lymph nodes and other health issues. The puppies were treated with a combination of prednisolone and sirolimus, a medication that helped reduce their symptoms significantly. Over time, some puppies showed marked improvement, with one even able to stop all medications and remain healthy. The treatment not only improved their overall health but also reduced the need for corticosteroids, leading to fewer side effects.
People also search for: Boerboel puppy swollen lymph nodes treatment · autoimmune disease in dogs · sirolimus for dogs · prednisolone side effects in puppies
Abstract
BACKGROUND: Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder caused by defective Fas cell surface death receptor-mediated lymphocyte apoptosis, resulting in chronic lymphadenomegaly, splenomegaly, and autoimmune cytopenias. Management of ALPS in dogs has not been reported previously. HYPOTHESIS/OBJECTIVES: Describe treatment, therapeutic drug monitoring (TDM), and clinical and laboratory outcomes in Boerboel dogs with genetically confirmed ALPS. ANIMALS: Four affected Boerboel pups from a litter studied prospectively and 2 retrospectively identified littermates from a different litter. METHODS: Prospective case series. All 4 index puppies received prednisolone and proprietary sirolimus; 3 subsequently received generic sirolimus. Clinical response was assessed through physical examinations, CBCs, serum biochemistry profiles, and TDM. Two additional affected dogs were reviewed retrospectively. RESULTS: Initiation of proprietary sirolimus in the index litter was associated with resolution or near resolution of lymphadenomegaly and abdominal distension, improvement in hematologic variables, and decreased corticosteroid requirements. Gastrointestinal signs improved but recurred intermittently in pups 1 and 4. By 10 months of age, pups 2 and 3 achieved sustained, marked clinical improvement. Notably, pup 2 had all drugs discontinued and remained clinically well. A fourteen-month follow-up showed sustained overall clinical improvement in the index litter. CONCLUSIONS AND CLINICAL IMPORTANCE: Autoimmune lymphoproliferative syndrome can cause clinically relevant morbidity in dogs. Sirolimus, alone or with prednisolone, appeared effective and well tolerated, decreasing corticosteroid requirements and adverse effects. Genetic screening and management with sirolimus focused on patient comfort were beneficial. Clinical signs appeared to improve with age in some individuals, suggesting that de-escalation or discontinuation of treatment may be possible in selected cases.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41742581/